2nd Quarter 2023 Financial Results & Business Update Legal Disclaimers This presentation and the accompanying oral presentation candidates, and our ability to serve those markets; our to time, whether as a result of new information, future contain “forward-looking” statements that are based on our commercialization, marketing and manufacturing capabilities and developments or otherwise. management’s beliefs and assumptions and on information strategy; current and future agreements with third parties in curr ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form10-Q 91361 (Zip Code) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number: 001-39186 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or Other ...

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Eric McIntyre - Head of Investor Relations Frank Watanabe - President & Chief Executive Officer Patrick Burnett - Chief Medical Officer Ken Lock - Chief Commercial Officer Scott Burrows - Chief Financial Officer Conference Call Participants Vikram Purohit - Morgan Stanley Seamus Fernandez - Guggenheim Securities Uy Ear - Mizuho Louise Chen - Cantor Greg Fraser - Truist Securities Sean Kim ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form10-Q 91361 (Zip Code) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number: 001-39186 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or Other ...

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET Company Participants Eric McIntyre - Head of Investor Relations Frank Watanabe - President & Chief Executive Officer Patrick Burnett - Chief Medical Officer Ken Lock - Chief Commercial Officer Scott Burrows - Chief Financial Officer Conference Call Participants Vikram Purohit - Morgan Stanley Seamus Fernandez - Guggenheim Ken Cacciatore - Cowen Greg Fraser - Truist Louise Chen - Cantor Rohit Bhasin - N ...

4th Quarter and Full Year 2022 Financial Results & Business Update February 28, 2023 Legal Disclaimers This presentation and the accompanying oral presentation contain "forward-looking" statements that are based on our management's beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our current and future financial performance, ...

Table of Contents Index to Financial Statements UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number: 001-39186 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charte ...

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q3 2022 Earnings Conference Call November 8, 2022 5:00 PM ET Company Participants Eric McIntyre - Head, IR Todd Watanabe - President, CEO & Director Kenneth Lock - Chief Commercial Officer Patrick Burnett - SVP & Chief Medical Officer Scott Burrows - CFO & Principal Accounting Officer Conference Call Participants Kenneth Cacciatore - Cowen Vikram Purohit - Morgan Stanley Louise Chen - Cantor Fitzgerald Serge Belanger - Needham & Company Seamus Fernandez - Guggenhe ...